Helus Pharma Surpasses 86% Enrollment In Phase 3 APPROACH Trial, Launches US $50 Million Offering

Helus Pharma said its Phase 3 APPROACH trial is now over 86% enrolled, indicating solid clinical progress for its mental-health pipeline. The company also priced a US$50 million underwritten offering to help fund development. The update is positive for execution and financing, though the immediate market impact should be limited to the stock.

Analysis

Helus Pharma said its Phase 3 APPROACH trial is now over 86% enrolled, indicating solid clinical progress for its mental-health pipeline. The company also priced a US$50 million underwritten offering to help fund development. The update is positive for execution and financing, though the immediate market impact should be limited to the stock.